US OptionsDetailed Quotes

LYEL250516C5000

Watchlist

0.00
0.000.00%

15min DelayClose May 2 09:30 ET

0.00High0.00Low

Lyell Immunopharma Stock Discussion

Teddy123

May 1 21:13

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma

$Lyell Immunopharma (LYEL.US)$
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Teddy123

Apr 16 13:22

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

$Lyell Immunopharma (LYEL.US)$
Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Trytosaveabit

Apr 15 21:14

news

$Lyell Immunopharma (LYEL.US)$ Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma

Jaguar8

Apr 15 21:09

NEWS

$Lyell Immunopharma (LYEL.US)$
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Tuesday, 15th April at 9:00 am
• RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.
• RMAT designation recognizes the potential of LYL314 to address significant unmet needs of ...

Trytosaveabit

Feb 14 04:46

Hmm! Like. They didn’t buy to lose money! Hehehe

$Lyell Immunopharma (LYEL.US)$ New 13G’s recently showing J&J and Black Rock Got some shares!

Teddy123

Dec 10, 2024 17:06

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

$Lyell Immunopharma (LYEL.US)$
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial

Wins333

Nov 21, 2024 04:11

$Lyell Immunopharma (LYEL.US)$ what a day

Teddy123

Nov 8, 2024 19:40

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

$Lyell Immunopharma (LYEL.US)$
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...

Teddy123

Nov 7, 2024 21:15

When will u start moving

$Lyell Immunopharma (LYEL.US)$

Teddy123

Nov 5, 2024 22:39

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

$Lyell Immunopharma (LYEL.US)$
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...

No comment yet